These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 24055310

  • 1. Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.
    Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, Ruiz FJ, Brazilian HCV-Related Advanced Fibrosis Study Group.
    Braz J Infect Dis; 2014; 18(1):48-52. PubMed ID: 24055310
    [Abstract] [Full Text] [Related]

  • 2. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M, Brazilian Pegasys Cooperative Study Group.
    Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].
    Božić M, Bojović K, Fabri M, Nožić D, Trkulja B, Milošević I.
    Srp Arh Celok Lek; 2012 Feb; 140(7-8):448-55. PubMed ID: 23092029
    [Abstract] [Full Text] [Related]

  • 4. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA.
    PLoS One; 2015 Feb; 10(12):e0143492. PubMed ID: 26640956
    [Abstract] [Full Text] [Related]

  • 5. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W, P05411 study investigators.
    Lancet Infect Dis; 2013 Jul; 13(7):597-605. PubMed ID: 23768747
    [Abstract] [Full Text] [Related]

  • 6. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.
    Clin Drug Investig; 2008 Jul; 28(1):9-16. PubMed ID: 18081356
    [Abstract] [Full Text] [Related]

  • 7. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H, Mori Y, Shingaki N, Kawashima A, Tsukuda H, Higashi K, Moribata K, Kawaguchi M, Ueda K, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M.
    Antivir Ther; 2014 Jul; 19(1):107-15. PubMed ID: 24162072
    [Abstract] [Full Text] [Related]

  • 8. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 9. The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study.
    Ferreira PR, Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC.
    Braz J Infect Dis; 2015 May; 19(1):15-22. PubMed ID: 25181403
    [Abstract] [Full Text] [Related]

  • 10. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H, Raza A, Waheed Y, Gill U, Gill ML.
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [Abstract] [Full Text] [Related]

  • 11. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
    Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE.
    Hepatology; 2015 Mar; 61(3):769-75. PubMed ID: 25322962
    [Abstract] [Full Text] [Related]

  • 12. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G.
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
    Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS.
    Antimicrob Agents Chemother; 2014 Jan; 58(2):1136-45. PubMed ID: 24295986
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.
    El Khayat HR, Fouad YM, El Amin H, Rizk A.
    Trop Gastroenterol; 2012 Jan; 33(2):112-7. PubMed ID: 23025057
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L.
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [Abstract] [Full Text] [Related]

  • 16. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK.
    J Hepatol; 2010 Apr; 52(4):501-7. PubMed ID: 20189674
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, González-Lassalle E, Salgado-Mercado R, Marxuach-Cuétara AM.
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [Abstract] [Full Text] [Related]

  • 18. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
    Fernández-Rodríguez CM, Morillas RM, Masnou H, Navarro JM, Bárcena R, González JM, Martín-Martín L, Poyato A, Miquel-Planas M, Jorquera F, Casanovas T, Salmerón J, Calleja JL, Solà R, Alonso S, Planas R, Romero-Gomez M.
    Gastroenterol Hepatol; 2014 Jan; 37(1):1-8. PubMed ID: 24360571
    [Abstract] [Full Text] [Related]

  • 19. Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
    Bourlière M, Ouzan D, Rosenheim M, Doffoël M, Marcellin P, Pawlotsky JM, Salomon L, Fagnani F, Rouanet S, Pinta A, Vray M.
    Antivir Ther; 2012 Jan; 17(1):101-10. PubMed ID: 22267474
    [Abstract] [Full Text] [Related]

  • 20. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N.
    J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.